z-logo
open-access-imgOpen Access
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Author(s) -
Philippe Moreau,
Tamás Masszi,
Norbert Grząśko,
Nizar J. Bahlis,
Markus Hansson,
Luděk Pour,
Irwindeep Sandhu,
Peter Ganly,
Bartrum W. Baker,
Sharon Jackson,
Anne-Marie Stoppa,
David R. Simpson,
Peter Gimsing,
Antonio Palumbo,
Laurent Garderet,
Michèle Cavo,
Shaji Kumar,
Cyrille Touzeau,
Francis K. Buadi,
Jacob P. Laubach,
Deborah Berg,
Jianchang Lin,
Alessandra Di Bacco,
Ai-Min Hui,
Helgi van de Velde,
Paul G. Richardson
Publication year - 2016
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1516282
Subject(s) - lenalidomide , ixazomib , medicine , multiple myeloma , dexamethasone , oncology , dermatology , pharmacology , carfilzomib
Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom